Home/Biosimilar Atlas/Companies/Finox Biotech

Finox Biotech

Biosimilar developer, Switzerland. 1 development product across 1 molecule: follitropin alfa.

First approval in the Atlas: Mar 2014, Bemfola, follitropin alfa (EMA)
FDAproducts approved0
EMAproducts approved1
MHRAproducts approved1
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered1
Connections
1molecule1product3 of 7markets0candidates in trials4companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Follitropin alfaBemfola·Mar 2014MHRA···Sep 20163/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Finox Biotech, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Intas PharmaceuticalsOne shared molecule: follitropin alfa12 molecules in its portfolioReliance Life SciencesOne shared molecule: follitropin alfa14 molecules in its portfolioTevaOne shared molecule: follitropin alfa5 molecules in its portfolioZydus LifesciencesOne shared molecule: follitropin alfa11 molecules in its portfolio

Chronology

Compare Finox Biotech with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.